A Phase 1/2 interventional study of RSV+HMPV vaccine and Control Vaccine 3 in Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization and Healthy Volunteers, sponsored by Sanofi. Recruiting at 50 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Sanofi · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older. The aim of the study is to evaluate the immunogenicity and safety of an RSV+HMPV vaccine candidate for the prevention of RSV and HMPV disease among adults 60 years of age and older. While there are 3 FDA approved/licensed RSV vaccines currently available to the public, no vaccine is available for the prevention of HMPV in older adults. This study is intended to provide data in support of further clinical development of the RSV+HMPV vaccine candidate.
The study will consist of 4 cohorts and 11 vaccine groups (RSV+HMPV [6 dose levels], placebo and 4 control groups).
The duration of the study will be approximately 12 months for each participant.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive RSV + HMPV vaccine corresponding to Dose 1 with a predefined antigen ratio
Biological: RSV+HMPV vaccine
Participants will receive RSV + HMPV vaccine corresponding to Dose 2 with a predefined antigen ratio
Biological: RSV+HMPV vaccine
Participants will receive RSV + HMPV vaccine corresponding to Dose 3 with a predefined antigen ratio
Biological: RSV+HMPV vaccine
Participants will receive RSV + HMPV vaccine corresponding to Dose 4 with a predefined antigen ratio
Biological: RSV+HMPV vaccine
Participants will receive RSV + HMPV vaccine corresponding to Dose 5 with a predefined antigen ratio
Biological: RSV+HMPV vaccine
Participants will receive RSV + HMPV vaccine corresponding to Dose 6 with a predefined antigen ratio
Biological: RSV+HMPV vaccine
Participants will receive control vaccine 1
Biological: Control Vaccine 1
Participants will receive Placebo
Other: Placebo
Participants will receive control vaccine 2 at a predefined dose and antigen ratio
Biological: Control Vaccine 2
Participants will receive control vaccine 3 at a predefined dose
Biological: Control Vaccine 3
Participants will receive control vaccine 4 at a predefined dose
Biological: Control Vaccine 4
RSV + HMPV Candidate Vaccine
Control Vaccine 3
Control Vaccine 4
Control Vaccine 2
Placebo
Control Vaccine 1
RSV A serum nAb (neutralizing antibodies) titers
nAb titers expressed as geometric mean titers (GMTs)
Time frame: At Day 1 and Day 29
RSV B serum nAb titers
nAb titers expressed as GMTs
Time frame: At Day 1 and Day 29
HMPV A serum nAb titers
nAb titers expressed as GMTs
Time frame: At Day 1 and Day 29
HMPV B serum nAb titers
nAb titers expressed as GMTs
Time frame: At Day 1 and Day 29
Unsolicited systemic Adverse Events (AEs) that occur within 30 minutes after vaccination
Number of participants reporting immediate unsolicited systemic AEs
Time frame: Within 30 minutes after vaccination
Presence of solicited injection site and systemic reactions
Number of participants reporting: * injection site reactions: pain, erythema and swelling * systemic reactions: fever, headache, fatigue and myalgia
Time frame: For 8 days, including the day of vaccination
Presence of Unsolicited AEs
Number of participants reporting unsolicited AEs
Time frame: For 28 days, including day of vaccination
Presence of medically attended AEs (MAAEs)
Number of participants reporting MAAEs
Time frame: Within 6 months after vaccination
Presence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Number of participants reporting SAEs and AESIs
Time frame: Throughout the study (approximately 12 months)
Presence of out-of-range biological test results
Number of participants with biological safety assessment values out of normal range (including shift from baseline values)
Time frame: At Day 09
RSV A serum nAb titers at 3, 6, 9, and 12 months post-vaccination
nAb titers expressed as geometric mean titers (GMTs)
Time frame: 3, 6, 9, and 12-months post-vaccination
RSV B serum nAb titers at 3, 6, 9, and 12 months post-vaccination
nAb titers expressed as GMTs
Time frame: 3, 6, 9, and 12 months post-vaccination
HMPV A serum nAb titers at 3, 6, 9, and 12 months post-vaccination
nAb titers expressed as GMTs
Time frame: 3, 6, 9, and 12 months post-vaccination
HMPV B serum nAb titers at 3, 6, 9, and 12 months post-vaccination
nAb titers expressed as GMTs
Time frame: 3, 6, 9, and 12 months post-vaccination
Serum RSV preF immunoglobulin G (IgG) Ab concentrations at pre-vaccination (Day 01), and at 28 days (Day 29), 3, 6, 9, and 12 months post-vaccination
Ab concentration expressed as geometric mean concentrations (GMCs)
Time frame: pre-vaccination (Day 01), and at 28 days (Day 29), 3, 6, 9, and 12 months post-vaccination
Serum HMPV preF immunoglobulin G (IgG) Ab concentrations at pre-vaccination (Day 01), and at 28 days (Day 29), 3, 6, 9, and 12 months post-vaccination
Ab concentration expressed as GMCs
Time frame: pre-vaccination (Day 01), and at 28 days (Day 29), 3, 6, 9, and 12 months post-vaccination
Ratio of RSV A and RSV B serum nAb titer fold-rise over anti-preF IgG Ab concentration fold-rise at Day 29, 3, 6, 9, and 12 months post-vaccination, from pre vaccination (Day 01)
Time frame: Day 29, 3, 6, 9, and 12 months post-vaccination, from pre-vaccination (Day 01)
Ratio of HMPV A and HMPV B serum nAb titer fold-rise over anti-preF IgG Ab concentration fold-rise at Day 29, 3, 6, 9, and 12 months post-vaccination, from pre vaccination (Day 01)
Time frame: Day 29, 3, 6, 9, and 12 months post-vaccination, from pre-vaccination (Day 01)
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.